Applying Experiences from Trials of Bacille Calmette-Guérin Vaccine
Clicks: 5
ID: 268428
2000
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
1.2
/100
5 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #1,024 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Bacille Calmette-Guérin (BCG) vaccine, a live vaccine developed to prevent tuberculosis (TB), has been given to billions of persons over more than 7 d
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (25 words).
Try re-searching for a better abstract.
| Reference Key |
e.2000clinicalapplying
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Wilson, Mary E.; |
| Journal | clinical infectious diseases |
| Year | 2000 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.